
==== Front
Ann Med
Ann Med
Annals of Medicine
0785-3890
1365-2060
Taylor & Francis

39297312
10.1080/07853890.2024.2401112
2401112
Version of Record
Review Article
Cardiology & Cardiovascular Disorders
Metabolic landscape in venous thrombosis: insights into molecular biology and therapeutic implications
Z. Cao et al.
Cao Zheng abc
Jiang Xuejun abc
He Yiyu abc
Zheng Xiaoxin abc
a Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China
b Cardiovascular Research Institute, Wuhan University, Wuhan, Hubei, China
c Hubei Key Laboratory of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China
CONTACT Xiaoxin Zheng xiaoxinzheng@whu.edu.cn Department of Cardiology, Renmin Hospital of Wuhan University, No. 238 Jiefang Road, Wuchang District, Wuhan 430060, Hubei, China.
19 9 2024
2024
19 9 2024
56 1 240111210 8 2023
20 3 2024
12 5 2024
KnowledgeWorks Global Ltd.18 9 2024
published online in a building issue18 9 2024
© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
2024
The Author(s)
https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

Abstract

The findings of the last decade suggest a complex link between inflammatory cells, coagulation, and the activation of platelets and their synergistic interaction to promote venous thrombosis. Inflammation is present throughout the process of venous thrombosis, and various metabolic pathways of erythrocytes, endothelial cells, and immune cells involved in venous thrombosis, including glucose metabolism, lipid metabolism, homocysteine metabolism, and oxidative stress, are associated with inflammation. While the metabolic microenvironment has been identified as a marker of malignancy, recent studies have revealed that for cancer thrombosis, alterations in the metabolic microenvironment appear to also be a potential risk. In this review, we discuss how the synergy between metabolism and thrombosis drives thrombotic disease. We also explore the great potential of anti-inflammatory strategies targeting venous thrombosis and the complex link between anti-inflammation and metabolism. Furthermore, we suggest how we can use our existing knowledge to reduce the risk of venous thrombosis.

Keywords

Venous thrombosis, metabolism
inflammatory
oxidative stress
National Natural Science Foundation of China 10.13039/501100001809 81800431 18 Natural Science Foundation of Hubei Province 10.13039/501100003819 2018CFB415 This work was supported by grants from the National Natural Science Foundation of China (Nos. 81800431 and 81800444) and the Natural Science Foundation of Hubei Province (No. 2018CFB415).
==== Body
pmcIntroduction

Deep venous thrombosis (DVT) and pulmonary embolism (PE) make up venous thromboembolism (VTE). According to the current global epidemiological statistics, the incidence of VTE varies widely by age, from 0.1 per 1,000 in adolescence to 8 per 1,000 in individuals in their eighties [1]. In the United States, at least 200,000 patients are diagnosed with PE each year [2,3], and approximately 100,000 to 180,000 people die from VTE each year [4]. Risk factors for lower extremity VTE are mostly acquired, including tumors, inflammation, prolonged braking, obesity, and antiphospholipid syndrome [5–8], differing from arterial thrombosis in that hyperlipidemia, hypertension, and diabetes [9]. The pathological mechanism of venous thrombosis is determined by the Virchow triad, including blood stasis, blood hypercoagulability, and vascular endothelial activation [10,11]. Numerous studies have shown the involvement of innate immune cells, such as neutrophils and mast cells, in the formation and propagation of venous thrombosis [12,13], and eosinophils seem to have less influence on the formation of venous thrombosis. In contrast, endothelial and immune cells have unique biochemical and histological features, such as oxidative stress, abnormal cellular metabolism, and mitochondrial abnormalities [14]. These may lead to abnormalities in their metabolic microenvironment, which in turn promote the formation of venous thrombosis. Current research on venous thrombosis has focused on the relationship between inflammation and thrombosis, in contrast to cellular metabolism, which has focused on oxidative stress and cellular autophagy. Cellular metabolism and products may promote inflammation, leading to cellular damage and oxidative stress, resulting in the promotion of thrombosis.

Anticoagulation is still the cornerstone of VTE treatment. Anti-inflammatory therapy might be not only effective in reducing the recurrence rate of VTE but could also be a proper way to avoid one of the more problematic aspects of anticoagulation – bleeding [15,16]. In addition to neutrophil extracellular traps (NETs), several more promising therapeutic targets are currently recognized, including Krüppel-like factor 2 and high mobility group protein-1 [17]. However, studies on the effects of cellular metabolism and the metabolic microenvironment on VTE formation are lacking. In this regard, we reviewed and outlined the impact of cellular metabolic status on VTE formation and the link to these two therapeutic targets to provide further insights into preventing and treating VTE.

Link between venous thrombosis and inflammation

Most nontraumatic deep vein thrombosis originates primarily in the valves and sinuses of the calf veins [18–20]. In contrast to arterial thrombosis, the composition of venous thrombosis generally contains a large number of red blood cells and is not associated with endothelial denudation [21]. The site of occurrence and the pathologic composition fully suggest that the mechanism of venous thrombosis differs significantly from that of arterial thrombosis. As shown in Figure 1, the traditional view of venous thrombosis is that activated platelets and monocytes bind to tissue factor (TF) on the endothelial cell membrane and then to coagulation factor VIIa, triggering a chain reaction of coagulase enzymes that results in the formation of a fibrin clot [22]. However, in the last decade, as the study of thrombosis has advanced, it has been recognized that there is a very close association between inflammation and thrombosis; for example, patients with neocoronavirus pneumonia who progress to respiratory failure are at very high risk of thrombosis [23–25]. In addition, it has been demonstrated that autoimmune diseases such as antiphospholipid syndrome, inflammatory myositis, polymyositis and dermatomyositis, rheumatoid arthritis, sarcoidosis, Sjogren’s syndrome, autoimmune hemolytic anemia, systemic lupus erythematosus, systemic sclerosis, vasculitis, and inflammatory bowel disease contain specific inflammatory pathophysiological mechanisms, leading to the risk of arterial and venous thrombosis [26].

Figure 1. The process of venous thrombosis and the risk factors for DVT.

More interestingly, inflammation seems to be involved in the whole process of venous thrombosis (Figure 2). Venous thrombosis is mainly formed in veins with low shear, and it has been demonstrated that low shear can trigger the recruitment of immune cells through the upregulation of the NF-κB pathway [27]. The recruited immune cells could deliver procoagulant factors that initiate the coagulation cascade, such as TF released by monocytes, activating the coagulation system in VTE formation [22]. In addition, the stagnant blood flow in veins could lead to the secretion of inflammatory factors by mast cells as well as endothelial cells (histamine, etc.), and this could also promote thrombosis [28].

Figure 2. The propagation of immunothrombosis by leukocytes and platelets. Under hypoxic conditions, ROS leads to an increase in HIF-1α, which in turn induces the expression of NLRP3 inflammatory vesicles in endothelial cells. This leads to the secretion of IL-1β and promotes platelet activation and thrombosis. ROS also leads to mast cell activation, histamine release and complement activation. These substances induce the release of vWF and P-selectin-containing WPB vesicles from endothelial cells, followed by the aggregation of natural immune cells and platelets on the endothelial surface. The combination of HMGB1 released from platelets, TLR2 from monocytes and CXCR2 from neutrophils induces the release of NETs, a process regulated mainly by the PAD4 enzyme. In addition, the release of tissue factor by monocytes activates the exogenous coagulation cascade. TLR2: Toll-like receptor 2; CXCR2: chemokine receptor 2; PSGL-1: P-selectin glycoprotein ligand 1; ROS: reactive oxygen species; HIF-1α: hypoxia inducible factor-1; IL: interleukin; vWF: von Willebrand Factor; WPB: Weibel-Palade body; HMGB: high-mobility group protein; NETs: neutrophil extracellular traps; PAD4: peptidylarginine deiminase 4.

Red blood cells

In clinical practice, erythrocytes were found to have a certain effect on coagulation, for example, the bleeding time of patients with anemia is prolonged even under normal platelet count conditions, and patients with true erythrocytosis have a certain risk of thrombosis [29,30]. However, the mechanisms by which erythrocytes alter coagulation are still unknown, and the effect on coagulation is currently attributed only to their effect on the rheology of the blood. Increasing of erythrocyte concentration leads to an increase in blood viscosity and thus promotes thrombosis [31,32]. Unlike normal double-sided depressed erythrocytes, in sickle cell disease, hemolytic anemia, and diabetes mellitus, erythrocytes with harder and poorly formed structure could promote platelets to free themselves from the edges of the vessels and finally promote thrombosis [33,34]. Additionally, when erythrocytes are stimulated by inflammatory factors, erythrocytes could produce relevant inflammatory particles [34,35], promoting the transfer of free heme to the vascular endothelium through the expression of tissue factor as well as phosphatidylserine, and the activation of thrombin-dependent complement, it then amplifies systemic inflammation, enhances the action of thrombin, and promotes the formation of blood clots [36]. Normal erythrocytes could display antithrombotic properties under certain conditions, for example, deoxygenated hemoglobin stimulates the release of NO from hemoglobin cysteine β93, leading to dilation of capillaries and reduced platelet reactivity [37].

White blood cells

Patients with systemic infections as well as multiple organ failure, the interaction between platelets and immune cells activates the coagulation system as well as the complement system to promote thrombosis, resulting in microvascular obstruction and the absence of blood supply to the tissues [17]. It has been suggested that the immune cells involved in venous thrombosis are mainly neutrophils, mast cells, etc. [38], and that neutrophils perform a variety of cellular functions during venous thrombosis, including oxidative bursting, phagocytosis, degranulation, secretion of a variety of inflammatory factors, and the formation of extracellular traps for neutrophils [39]. It has been demonstrated that the primary metabolic pathway of neutrophils is glycolysis, but under conditions of low glucose availability, neutrophils could activate fatty acids for compensatory metabolism and utilize glutamate dehydrogenase to produce α-ketoglutarate to energize the TCA cycle [40,41]. Due to the low oxygen content of venous thrombi, neutrophils inhibit apoptosis by producing a number of glycolytic enzymes, including GAPDH, to produce ATP to maintain neutrophil survival and function [42,43].

Platelet and platelet microvesicles

Platelets are important circulating cells, which are required to interact with inflammatory cells, and endothelial cells during thrombus formation [17]. The metabolism of activated platelets includes process of mitochondrial depolarization, ROS-dependent signaling, extensive cytoskeletal reorganization, and rapid protein synthesis [44–47]. In the setting of venous thrombosis, platelets are limited by nutrient as well as oxygen supply. Well-coupled mitochondria in platelets promote to produce ATP through glycolysis and oxidative phosphorylation [48]. In resting platelets, nearly 60% of the ATP comes from glycolysis, and the remaining 40% comes from oxidative phosphorylation [49]. When platelets are activated, the glucose transporter protein GLUT3 is overexpressed on the surface of the platelets, which enhances the uptake of glucose [50]. It has been demonstrated that the metabolism of activated platelets favors glycolysis over oxidative phosphorylation [48], which seems to correlate with oxygen- and nutrient-poor conditions in thrombi.

PMV(platelet microvesicles) is an extracellular vesicle differentiated from activated platelet membranes [51], which can mediate cell signaling by carrying cellular metabolites, lipids, proteins, and nucleic acids between cells and organs, and thus represents a new mode of intercellular communication in metabolic regulation [52,53]. Studies have now demonstrated that PMV is highly procoagulant, and more interestingly, under some pathological conditions, PMV can express tissue factor which in turn triggers blood coagulation [54], and there are already clinical data suggesting that a high percentage of PMV in plasma is a risk marker for future VTE [55]. The plasma levels of PMV are significantly higher in glucose-tolerant and diabetic patients, whose blood glucose may have a role in promoting the generation of PMV [56], PMV can promote the formation of venous thrombosis due to the presence of CD41, CD42b, and phosphatidylserine [57], and in addition, PMV can promote the production of inflammatory factors, such as IL-1, IL-6, and IL-8, which can in turn promote the formation of thrombi [58]. In addition to blood glucose can affect PMV, ROS can also have some effect on PMV, for example, nitric oxide synthase-2 and NADPH oxidase in neutrophils can promote the production of ROS, which in turn promotes the production of PMV [59].

Mechanisms of influence of the metabolic microenvironment on DVT

The identification of risk factors for venous thrombosis is essential for thromboprophylaxis in individuals. As shown in Figure 1, risk factors have been stratified Numerous studies have suggested that lipoproteins, blood glucose levels, and homocysteine are potential risk factors for VTE [60]. The metabolism of these substances is closely linked to inflammation (Figure 3), and we outline below the relationship between the metabolism of these types of substances and thrombosis.

Figure 3. Erythrocytes and their cells metabolize sugars and secrete lactic acid and other acidic substances, resulting in an acidic microenvironment. After converting macrophages from the M1 type to the M2 type, M2-type macrophages secrete various inflammatory factors (IL-1, IL-8, and TNF-α) that promote the aggregation of immune cells and thrombus formation. Lipids and metabolites affect the fluidity of immune cells and platelet membranes, exacerbating their aggregation and activating their surface receptors (TLR and PPAR receptors). This leads to the recognition of immune cells by platelets and further promotes thrombus formation. IL: interleukin; TNF: tumor necrosis factor; TLR: Toll-like receptor; PPAR: peroxisome proliferator-activated receptor.

Glucose metabolism

There have been many studies describing age, obesity, and smoking as risk factors for DVT, with little mention of blood glucose [6]. However, in a study in Taiwan comparing 4967 patients with type 1 diabetes and 19,868 normal people, at a mean follow-up of 8.61 years, 0.3% of patients in the control group developed VTE, while 1.6% of patients in the diabetes group developed VTE [61]. In a recent clinical trial, it was found that the risk of pulmonary embolism was increased in patients undergoing hip and knee arthroplasty with preoperative blood glucose levels exceed 11.1 mmol/l [62]. Since the origin of DVT is usually in the deepest depression of the valve sinus at the valve site [21], hypoxia and high blood viscosity in this area are likely to induce changes in platelet and red blood cell glucose metabolism, which in turn promotes thrombosis.

The metabolites of thrombi are derived from erythrocytes, platelets and leukocytes in that order, so the metabolism of erythrocytes is likely to have a major impact on thrombosis. Generally, the tricarboxylic acid cycle process in glycolysis is the main way for cells to obtain energy. However, the cells involved in thrombosis do not receive an adequate supply of oxygen; therefore, cells in thrombi may not be able to carry out normal glucose metabolism [63]. It has been demonstrated that erythrocyte metabolism under hypoxic conditions is mainly dependent on competition between deoxyhemoglobin and glycolytic enzymes for the structural domain of band III cytoplasm [64], which is the main transmembrane protein of erythrocytes and has a strong affinity for deoxyhemoglobin and glycolytic enzymes (phosphofructokinase, lactate dehydrogenase, aldolase, etc.). Thus, it can inhibit the glycolytic pathway [64,65], resulting in an increase in lactate levels. In addition, thrombin-stimulated platelets could produce lactate [66], which is the most abundant metabolite in blood clots. Lactic acid itself could enhance blood coagulation and shorten whole blood clotting time in vivo and in vitro [67]. The acidic microenvironment caused by lactic acid also plays an important role in venous thrombosis. For example, macrophages can polarize in the acidic microenvironment and shift from the M1 phenotype to the M2 phenotype [68–70], and M2 phenotype macrophages can promote angiogenesis and secrete a variety of cytokines, such as basic fibroblast growth factor (BFGF), vascular endothelial growth factor (VEGF), interleukin-1 (IL-1), interleukin-8 (IL-8), tumor necrosis factor (TNFα) and nitric oxide [71–73]. Among these, TNFα can generate nitric oxide in the vessel wall to reduce platelet activation. In addition, TNFα acts on tumor necrosis factor receptor 2 (TNFR2) receptors to promote thrombosis [74,75]. A reduction in the size of the thrombus could be found after injecting sufficient TNFα into WT mice [75,76]. This may be because TNFα could improve fibrinolysis and collagenolysis and promote thrombus dissolution.

Hyperglycemia itself could lead to a hypercoagulable state of the blood [77], as well as reduced fibrinogen survival [78], indirectly promoting thrombosis. In addition, temporary hyperglycemia was found to activate platelet activity by activating PKC in platelets [79]. In addition, insulin, which is associated with hyperglycemia, seems to be involved in platelet activation [80]. It could cause the phosphorylation of endothelial nitric oxide synthase (eNOS), regulating NO synthesis and release [81,82]. NO activates guanylate cyclase through branched diffusion, leading to increased cGMP. The latter promotes vasodilation and the inhibition of platelet activity [83]. In summary, hyperglycemia itself has a thrombosis-promoting effect. The next point that has attracted more attention in recent years is advanced glycation end products (AGEs), which are the products of excess sugar and protein binding, and the AGE/receptor for advanced glycation end products (RAGE) axis, which is closely associated with inflammation and oxidative stress [84]. In a recent study, RAGE inhibition significantly suppressed lipid peroxidation malondialdehyde (MDA) and ROS levels in glycosylated human serum albumin (M-HSA)-stimulated mice, as well as endothelin-1 (ET-1) levels. In a previous study, it was shown that increased ET-1 expression may be involved in microthrombosis in retinal veins, which may complement the possibility of thrombosis [85]. In addition, blocking the AGE/RAGE pathway downregulated ET-1, which in turn reduced the damage to human umbilical endothelial cells (HUVECs) [86].

Lipid metabolism

Previous studies have confirmed that lipids have a relatively important effect on arterial thrombosis, mainly in terms of hemostasis and fibrinolysis in patients [87–89]. Studies in recent years have shown that lipid-induced changes in the coagulation system are not only found in arterial thrombosis but are also detectable in venous thrombosis [90]. The lipids that have attracted the most attention are triglycerides, lipoproteins and cholesterol. High levels of triglycerides not only increase blood stasis [91] but also promote venous thrombosis by inhibiting tissue fibrinogen activator activity and increasing fibrinogen activator inhibitor-1 (PAI-1) with reduced fibrinolysis [92]. Lipoproteins also play a central role in the development and progression of venous thrombosis [93]. Low-density lipoprotein (LDL) is a complex lipoprotein containing different lipids, including triglycerides, phospholipids, and free cholesterol [94]. Oxidized LDL (OxLDL) affects thrombosis in various ways. OxLDL activates platelets by recognizing cluster of differentiation 36 (CD36) on platelets, and then, activated platelets exacerbate lipoprotein oxidation, further inducing thrombotic inflammation [95,96]. OxLDL can also induce platelets to form aggregates with monocytes, resulting in thrombosis [97]. Oxidized cholesteryl esters present in OxLDL could induce monocyte adhesion on top of endothelial cells and promote blood coagulation [98]. Oxidized phospholipids (OxPLs) isolated from the least oxidized LDL could stimulate endothelial cells to express B1 integrins as well as P-selectin, IL-8, and vascular endothelial growth factor [99–101] to induce monocyte recruitment and adhesion at the endothelium. OxLDL could upregulate the expression of the CD11b-CD18 adhesion receptor complex on neutrophil membranes and thus mediate neutrophil adhesion and migration [102]. Lysophosphatidylcholine in OxLDL has been shown to induce extracellular traps in neutrophils and promote thrombus formation [103]. Moreover, OxLDL could delay blood clotting by inhibiting the activity of coagulation factors VIII, IX and XI [104,105]. It has also been shown that OxLDL and OxPL could increase prothrombin activity and thrombin production [106,107]. The current inhibitory effect of oxidized lipoproteins on blood clotting may be weaker than their effective activation of vascular cells.

In some relevant Mendelian randomization trials, no significant causal relationship was found between the three classical lipids (LDL, HDL, and total cholesterol) and VTE, whereas there was an association between VTE and fatty acids [108]. Fatty acids and metabolites can affect different immune cell populations, including neutrophils and macrophages, by regulating the fluidity of cell membranes [109]. In addition, they are able to activate relevant recognition receptors on the cell membrane, such as Toll-like receptors (TLRs) and peroxisome proliferator-activated receptors (PPARs), in the nuclear receptor family [109]. Neutrophils recognize platelets through TLR receptors and trigger the formation of neutrophil extracellular traps [110,111], leading to thrombosis. PPAR contains three isoforms: PPARα, PPARβ, and PPARγ. They are highly expressed in oxidative tissues and regulate oxidative phosphorylation and substrate oxidation [112–114]. In addition, PPAR has a wide range of natural ligands, including fatty acids, acyl coenzyme A and glycerophospholipids [115,116], making it a very important regulator of lipid metabolism. Hyperlipidemia promotes high expression of PPARα in platelets and mediates platelet activation and thus thrombus formation by regulating downstream p38 and Akt to promote the secretion of mitogenic bodies [117]. High-density lipoprotein (HDL) could inhibit thrombosis by affecting exogenous coagulation pathways and fibrinolysis and reducing blood viscosity [118]. HDL can also inhibit tissue factor and inactivate coagulation factors Va and VIIIa in the presence of activated protein C [119]. Moreover, docosahexaenoic acid (DHA) has anti-inflammatory effects by reducing nuclear factor κB (NF-κB) in peripheral blood mononuclear cells and TNFα mRNA expression in peripheral blood mononuclear cells [120].

Hypoxic conditions and oxidative stress

Current epidemiological statistics show a significant increase in the incidence of deep vein thrombosis and pulmonary embolism in populations at high altitudes [121–123]. Several studies have demonstrated that the hypoxic response could lead to platelet, endothelial and lymphocyte activation and thus promote inflammatory thrombosis [124,125]. Significantly elevated levels of NLRP3, interleukin (IL)-1β, IL-18 and cystatin-1 in peripheral blood could be observed from environments where DVT occurs at high altitude [126–128]. Hypoxia induces high expression levels of IL-1β in platelets [110,129–131] and upregulates IL-1β and NLRP3 in monocytes [126,132]. IL-1β can induce platelet activation and enhance platelet hyperresponsiveness, promoting platelet aggregation [133]. Activation of NLRP3 inflammatory vesicles could trigger aeroderm D-dependent lytic pyroptosis in macrophages, which in turn leads to the secretion of tissue factor by macrophages and promotes thrombosis [134]. In addition, hypoxia has also been shown to increase Ca21 in the platelet cytoplasm and thus activate calpain in the platelet membrane to promote thrombosis [135,136].

Age, an independent risk factor for VTE, is often associated with oxidative stress [137,138], as aging is characterized by excessive production of reactive oxygen species (ROS) [139]. ROS promote venous thrombosis by increasing the expression of tissue factor in endothelial cells and monocytes, activating platelets, and inducing thrombotic inflammation [140]. Erythrocytes are a major source of ROS, and they release large amounts of ROS through the activation of NADPH oxidase and oxidation of hemoglobin [141]. ROS could facilitate the influx of calcium ions by activating calcium channels that not only disrupt the erythrocyte membrane but also expose phosphatidylserine on the erythrocyte membrane, which further activates thrombinogen [142,143]. Erythrocyte membrane damage leads to the release of free hemoglobin and heme, which further activates hypoxia-inducible factor (HIF) production via the TOLL-like receptor signaling pathway. This further induces inflammation and increases endothelial permeability [144]. When this redox heme is transferred to endothelial cells, it can trigger H2O2-mediated endothelial damage, stimulating neutrophil recruitment and the formation of NETs and NLRP3 inflammatory vesicles [145]. In addition, ROS can oxidize arachidonic acid to activate platelets and affect the expression of P-selectin and soluble CD40L on the platelet surface to promote platelet–leukocyte interactions [146–148]. It has been shown that ROS could also induce the expression of adhesion molecules on immune cells to promote the recruitment and activation of immune cells [149], and it could activate calcium channels on mast cells. This leads to an increase in the concentration of calcium ions in the mast cell cytoplasm and promotes mast cell degranulation [150]. In addition, a link between mast cell degranulation and venous thrombosis has been previously demonstrated [28].

Homocysteine metabolism

The hypothesis that hyperhomocysteinemia is a causal risk factor for venous thrombosis is currently speculated in the results of a number of ‘Mendelian randomization’ trials [151]. Homocysteine is one of the more important amino acids in the body. When various factors induce the accumulation of homocysteine in the blood, excessive homocysteine results in cell, tissue, and organ damage [152]. Additionally, current research on HCY demonstrates that HCY can induce the expression of vascular cell adhesion molecule-1 (VCAM-1) in endothelial cells to enhance the adhesion of monocytes to endothelial cells [153,154]. HCY could also disrupt tissue mitochondrial singlet transport chain complex I. This leads to damage to the electron transport cascade, which in turn promotes the production of ROS in mitochondria. This process causes damage to cellular tissues and inflammation [155]. Therefore, clinically, homocysteine is an effective independent risk factor for degenerative diseases such as cardiovascular disease, chronic kidney disease and diabetes [156]. The metabolic process is divided into two categories: 1) HCY is converted to methionine by remethylation; and 2) HCY is converted to cysteine by the action of cystathionase condensing enzyme and cystathionase [157]. Methionine metabolism is involved in many cellular functions, including methylation reactions, redox maintenance, and folate metabolism [158]. Some studies suggest that methionine obtained in the diet could have a significant impact on cellular metabolism [158]. However, few studies on methionine metabolism and venous thrombosis are still lacking.

Therapeutic targets

The current targets of antiplatelet therapy are mainly platelet activating receptors as well as cyclooxygenase [159]. Compared to arterial thrombosis, platelet activation is weaker in venous thrombosis [160]; therefore, the therapeutic effect of antiplatelet aggregation pharmacotherapy for venous thrombosis is not effective. However, on the other hand, platelet metabolism has an impact on thrombus formation. For example, platelet glycolysis could drive NADPH synthesis via the pentose phosphate pathway, leading to ROS production [161] and thrombogenesis. Pyruvate dehydrogenase kinase (PDK) and pyruvate kinase M2 (PKM2) are key enzymes in platelet glycolysis [162], but there is no concrete evidence to prove whether they have a certain effect on venous thrombus formation. Although the cornerstone of current treatment for venous thrombosis is anticoagulation, the risk of bleeding is not negligible [15]. Thus, anti-inflammation seems to hold great promise in the field of treating venous thrombosis. There are already studies that demonstrate feasibility. Such studies reported the use of deoxyribonuclease I (DNaseI) to inhibit venous thrombosis by pharmacologically disrupting NETs [163] and inhibiting receptors recognized by high mobility group protein-1 (HMGB1), including RAGE, TLR2, TLR4, and other receptors to inhibit venous thrombosis [164]. These inflammatory targets are highly associated with the metabolic microenvironment. For example, it has been shown that hyperglycemia could increase the release of NETs in patients with type II diabetes [165]. In addition, venous thrombosis can lead to unstable circulation and inadequate perfusion, so tissues are susceptible to ischemia, hypoxia, and consequently oxidative stress [166], so some specific markers of oxidative stress can be used as markers in the diagnosis of venous thrombosis as well as in the treatment of venous thrombosis. It has been demonstrated that malondialdehyde and reactive oxygen species levels are increased in patients with venous thrombosis [166], and that these substances are involved in the oxidative stress response. In addition, asymmetric dimethylarginine (ADMA), an amino acid commonly found in tissues that causes vasoconstriction and damage to endothelial cells [167], has been shown to be significantly elevated in patients with PTE [168]. Elevated levels of myeloperoxidase (MPO), a member of the heme peroxidase superfamily, are associated with increased inflammation and oxidative stress, and in patients with venous thrombosis, elevated levels are often associated with poor prognosis [169].

Activated neutrophils are responsible for promoting venous thrombosis through multiple mechanisms, and the three most prominent mechanisms are the production of tissue factors, the release of neutrophil extracellular traps, and the activation of inflammatory vesicles [170]. NETs are composed of nuclear DNA, histones, and neutrophil nuclear-derived granule proteins. NET production and release are mainly influenced by two enzymes, namely, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and nuclear peptidylarginine deaminase 4 (PAD4) [171,172]. Guanylated histone H3 in NETs can interact with vascular hemophilia factor (vWF) to promote thrombosis [173]. In addition to activating coagulation factor XII to activate the coagulation cascade to enhance venous thrombosis [174], NETs have now been shown to hydrolyze tissue factor pathway inhibitors to indirectly promote thrombin and fibrin clot production [175].

Glucose is a metabolic substrate and a major source of energy for neutrophils, which express the specific glucose transport proteins glucose transporter protein 1 (GLUT1) and glucose transporter protein-4 (GLUT4) on their cell membrane surface [176,177]. However, compared to other cells, neutrophils have fewer mitochondria, and they rarely participate in adenosine triphosphate synthesis [178]. Thus, the formation of NETs is mainly dependent on glycolysis. Therefore, glucose metabolism has a certain influence on the synthesis and release of neutrophils and NETs. For example, glucose overload and deficiency could affect the chemotaxis and phagocytosis of neutrophils [179]. In addition, it has been suggested that the release of NETs is strictly dependent on exogenous glucose and glycolysis. Therefore, the formation of NETs could be completely inhibited by using glycolysis inhibitors [41]. Oxidative phosphorylation and pentose phosphate pathways are not the main energy sources of NETs, but they function as secondary messengers to regulate the synthesis of NETs [180–182]. For example, the purinergic receptor P2X1 acts as a relevant signaling pathway for NETs [183]. The pentose phosphate pathway is involved in the production of NADPH oxidase-dependent ROS, which indirectly promotes the formation of NETs [184]. However, studies on whether fatty acids and other metabolites affect the synthesis and release of NETs are lacking. Neutrophils are the main source of ROS, and oxidative stress in NETs is highly associated with ROS. For NETs in the NADPH enzyme-dependent pathway, it has been shown that NADPH oxidase or ROS scavengers could inhibit NET formation. However, experimental data on whether they have an effect on venous thrombosis are not sufficient [185].

Conclusions

The cellular metabolism involved in venous thrombosis is often accompanied by the pathological processes of oxidative stress and cellular autophagy, which are often associated with inflammation. ROS have been shown to promote the release of inflammatory factors and the synthesis and release of neutrophil extracellular traps that promote thrombosis. Blood glucose concentrations can cause platelet activation and modulation of NO secretion in vascular endothelial cells, intermittently promoting thrombosis. In addition, glucose, as a major substrate of cellular metabolism, is metabolized by pathways including oxidative phosphorylation, the pentose phosphate pathway, and glycolysis. These pathways can indirectly affect venous thrombosis by affecting neutrophils and other cells as secondary messengers and receptor ligands. Additionally, these metabolites (ATP, lactate, pyruvate) not only lead to the production of inflammatory factors, such as tumor necrosis factor-α (TNF-α), by immune cells to indirectly affect thrombosis but also increase platelet activity, synthesis and release of extraneutrophil traps and vasoconstriction. Lipids and corresponding metabolites can reduce blood flow and alter platelet membrane fluidity, leading to blood stasis. Moreover, lipid metabolism in macrophages has been shown to be associated with inflammation and the release of inflammatory factors involved in venous thrombosis. Several anti-inflammatory strategies have been proposed for venous thrombosis, and one of the more intriguing strategies is the neutrophil extracellular trap. Glucose is an important source of energy for cells and has a major impact on the formation of NETs. ROS produced by cellular metabolism can also influence the formation of NETs. Therefore, based on these theories, new developments in the field of nutrition, including intermittent fasting and CR diets, have recently been shown to have an important role in the prevention of thrombosis; however, when considering the translation of these interventions into clinical treatment, we need more research on metabolism and venous thrombosis.

Ethical approval

All authors declare that there is no ethical issues to declare in relation to the research presented in this manuscript. We have conducted all the text in accordance with the relevant ethical standards and have disclosed any potential conflicts of interest.

Consent for publication

All authors consent for publication.

Author contributions

All of the authors contributed to the manuscript preparation. CZ, JXJ and HYY structured the manuscript and contributed to the figures. ZXX and JXJ revised the manuscript and confirmed the final revision.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

Data sharing is not applicable to this article as no new data were created or analyzed in this study.
==== Refs
References

1 Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5 (4 ):692–699. doi: 10.1111/j.1538-7836.2007.02450.x.17367492
2 Coon WW. Epidemiology of venous thromboembolism. Ann Surg. 1977;186 (2 ):149–164. doi: 10.1097/00000658-197708000-00006.329779
3 Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001;86 (1 ):452–463. doi: 10.1055/s-0037-1616243.11487036
4 MacDougall DA, Feliu AL, Boccuzzi SJ, et al. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm. 2006;63 (20 Suppl 6 ):S5–S15. doi: 10.2146/ajhp060388.
5 Wattanakit K, Lutsey PL, Bell EJ, et al. Association between cardiovascular disease risk factors and occurrence of venous thromboembolism. A time-dependent analysis. Thromb Haemost. 2012;108 (3 ):508–515. doi: 10.1160/TH11-10-0726.22782466
6 Gregson J, Kaptoge S, Bolton T, et al. Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol. 2019;4 (2 ):163–173. doi: 10.1001/jamacardio.2018.4537.30649175
7 Lutsey PL, Virnig BA, Durham SB, et al. Correlates and consequences of venous thromboembolism: the Iowa Women’s Health Study. Am J Public Health. 2010;100 (8 ):1506–1513. doi: 10.2105/AJPH.2008.157776.19910349
8 Severinsen MT, Kristensen SR, Johnsen SP, et al. Anthropometry, body fat, and venous thromboembolism: a Danish follow-up study. Circulation. 2009;120 (19 ):1850–1857. doi: 10.1161/CIRCULATIONAHA.109.863241.19858417
9 Mahmoodi BK, Cushman M, Anne Næss I, et al. Association of traditional cardiovascular risk factors with venous thromboembolism: an individual participant data meta-analysis of prospective studies. Circulation. 2017;135 (1 ):7–16. doi: 10.1161/CIRCULATIONAHA.116.024507.27831499
10 Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;451 (7181 ):914–918. doi: 10.1038/nature06797.18288180
11 Mackman N. New insights into the mechanisms of venous thrombosis. J Clin Invest. 2012;122 (7 ):2331–2336. doi: 10.1172/JCI60229.22751108
12 Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol. 2010;47 (13 ):2170–2175. doi: 10.1016/j.molimm.2010.05.009.20621693
13 Polley MJ, Nachman R. The human complement system in thrombin-mediated platelet function. J Exp Med. 1978;147 (6 ):1713–1726. doi: 10.1084/jem.147.6.1713.681879
14 Gorbunova V, Seluanov A, Mita P, et al. The role of retrotransposable elements in ageing and age-associated diseases. Nature. 2021;596 (7870 ):43–53. doi: 10.1038/s41586-021-03542-y.34349292
15 Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet. 2012;379 (9828 ):1835–1846. doi: 10.1016/S0140-6736(11)61904-1.22494827
16 Nieto JA, Solano R, Ruiz-Ribó MD, et al. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. J Thromb Haemost. 2010;8 (6 ):1216–1222. doi: 10.1111/j.1538-7836.2010.03852.x.20345727
17 Stark K, Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol. 2021;18 (9 ):666–682. doi: 10.1038/s41569-021-00552-1.33958774
18 Sevitt S, Gallagher N. Venous thrombosis and pulmonary embolism. A clinico-pathological study in injured and burned patients. Br J Surg. 1961;48 (211 ):475–489. doi: 10.1002/bjs.18004821103.13750445
19 McLachlin AD, McLachlin JA, Jory TA, et al. Venous stasis in the lower extremities. Ann Surg. 1960;152 (4 ):678–685. doi: 10.1097/00000658-196010000-00011.13774059
20 Browse NL, Thomas ML. Source of non-lethal pulmonary emboli. Lancet. 1974;1 (7851 ):258–259. doi: 10.1016/s0140-6736(74)92559-8.4130258
21 Sevitt S. The structure and growth of valve-pocket thrombi in femoral veins. J Clin Pathol. 1974;27 (7 ):517–528. doi: 10.1136/jcp.27.7.517.4138834
22 Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost. 2001;85 (06 ):958–965. doi: 10.1055/s-0037-1615947.11434702
23 Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383 (2 ):120–128. doi: 10.1056/NEJMoa2015432.32437596
24 Nicolai L, Leunig A, Brambs S, et al. Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy. Circulation. 2020;142 (12 ):1176–1189. doi: 10.1161/CIRCULATIONAHA.120.048488.32755393
25 Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75 (23 ):2950–2973. doi: 10.1016/j.jacc.2020.04.031.32311448
26 Menichelli D, Cormaci VM, Marucci S, et al. Risk of venous thromboembolism in autoimmune diseases: a comprehensive review. Autoimmun Rev. 2023;22 (11 ):103447. doi: 10.1016/j.autrev.2023.103447.37714419
27 Chiu J-J, Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev. 2011;91 (1 ):327–387. doi: 10.1152/physrev.00047.2009.21248169
28 Ponomaryov T, Payne H, Fabritz L, et al. Mast cells granular contents are crucial for deep vein thrombosis in mice. Circ Res. 2017;121 (8 ):941–950. doi: 10.1161/CIRCRESAHA.117.311185.28739590
29 Duke WW. The relation of blood platelets to hemorrhagic disease. JAMA. 1983;250 (9 ):1201–1209.6348329
30 Dicato M. Venous thromboembolic events and erythropoiesis-stimulating agents: an update. Oncologist. 2008;13 Suppl 3 (S3 ):11–15. doi: 10.1634/theoncologist.13-S3-11.18458119
31 Hellem AJ, Borchgrevink CF, Ames SB. The role of red cells in haemostasis: the relation between haematocrit, bleeding time and platelet adhesiveness. Br J Haematol. 1961;7 (1 ):42–50. doi: 10.1111/j.1365-2141.1961.tb00318.x.13713094
32 Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368 (1 ):22–33. doi: 10.1056/NEJMoa1208500.23216616
33 Vayá A, Suescun M, Hernández JL, et al. Rheological red blood cell behaviour in minor α-thalassaemia carriers. Clin Hemorheol Microcirc. 2011;48 (4 ):241–246. doi: 10.3233/CH-2011-1416.22012829
34 van Gelder JM, Nair CH, Dhall DP. Erythrocyte aggregation and erythrocyte deformability modify the permeability of erythrocyte enriched fibrin network. Thromb Res. 1996;82 (1 ):33–42. doi: 10.1016/0049-3848(96)00048-5.8731507
35 Heijnen HF, Schiel AE, Fijnheer R, et al. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood. 1999;94 (11 ):3791–3799.10572093
36 Zecher D, Cumpelik A, Schifferli JA. Erythrocyte-derived microvesicles amplify systemic inflammation by thrombin-dependent activation of complement. Arterioscler Thromb Vasc Biol. 2014;34 (2 ):313–320. doi: 10.1161/ATVBAHA.113.302378.24311376
37 Sun C-W, Yang J, Kleschyov AL, et al. Hemoglobin β93 cysteine is not required for export of nitric oxide bioactivity from the red blood cell. Circulation. 2019;139 (23 ):2654–2663. doi: 10.1161/CIRCULATIONAHA.118.039284.30905171
38 Uderhardt S, Ackermann JA, Fillep T, et al. Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease. J Exp Med. 2017;214 (7 ):2121–2138. doi: 10.1084/jem.20161070.28566277
39 Leliefeld PHC, Wessels CM, Leenen LPH, et al. The role of neutrophils in immune dysfunction during severe inflammation. Crit Care. 2016;20 (1 ):73. doi: 10.1186/s13054-016-1250-4.27005275
40 Kumar S, Dikshit M. Metabolic insight of neutrophils in health and disease. Front Immunol. 2019;10 :2099. doi: 10.3389/fimmu.2019.02099.31616403
41 Rodríguez-Espinosa O, Rojas-Espinosa O, Moreno-Altamirano MMB, et al. Metabolic requirements for neutrophil extracellular traps formation. Immunology. 2015;145 (2 ):213–224. doi: 10.1111/imm.12437.25545227
42 Gaber T, Strehl C, Buttgereit F. Metabolic regulation of inflammation. Nat Rev Rheumatol. 2017;13 (5 ):267–279. doi: 10.1038/nrrheum.2017.37.28331208
43 Curi TC, de Melo MP, de Azevedo RB, et al. Glutamine utilization by rat neutrophils. Biochem Soc Trans. 1997;25 (2 ):249S–249S. doi: 10.1042/bst025249s.9191293
44 Weyrich AS, Schwertz H, Kraiss LW, et al. Protein synthesis by platelets: historical and new perspectives. J Thromb Haemost. 2009;7 (2 ):241–246. doi: 10.1111/j.1538-7836.2008.03211.x.18983498
45 Hartwig JH. Mechanisms of actin rearrangements mediating platelet activation. J Cell Biol. 1992;118 (6 ):1421–1442. doi: 10.1083/jcb.118.6.1421.1325975
46 Remenyi G, Szasz R, Friese P, et al. Role of mitochondrial permeability transition pore in coated-platelet formation. Arterioscler Thromb Vasc Biol. 2005;25 (2 ):467–471. doi: 10.1161/01.ATV.0000152726.49229.bf.15591217
47 Begonja AJ, Gambaryan S, Geiger J, et al. Platelet NAD(P)H-oxidase-generated ROS production regulates alphaIIbbeta3-integrin activation independent of the NO/cGMP pathway. Blood. 2005;106 (8 ):2757–2760. doi: 10.1182/blood-2005-03-1047.15976180
48 Kulkarni PP, Tiwari A, Singh N, et al. Aerobic glycolysis fuels platelet activation: small-molecule modulators of platelet metabolism as anti-thrombotic agents. Haematologica. 2019;104 (4 ):806–818. doi: 10.3324/haematol.2018.205724.30381300
49 Melchinger H, Jain K, Tyagi T, et al. Role of platelet mitochondria: life in a nucleus-free zone. Front Cardiovasc Med. 2019;6 :153. doi: 10.3389/fcvm.2019.00153.31737646
50 Sorbara LR, Davies-Hill TM, Koehler-Stec EM, et al. Thrombin-induced translocation of GLUT3 glucose transporters in human platelets. Biochem J. 1997;328 (Pt 2) (Pt 2 ):511–516. doi: 10.1042/bj3280511.9371709
51 Owens AP, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res. 2011;108 (10 ):1284–1297. doi: 10.1161/CIRCRESAHA.110.233056.21566224
52 O’Neill S, Bohl M, Gregersen S, et al. Blood-based biomarkers for metabolic syndrome. Trends Endocrinol Metab. 2016;27 (6 ):363–374. doi: 10.1016/j.tem.2016.03.012.27150849
53 Martínez MC, Andriantsitohaina R. Extracellular vesicles in metabolic syndrome. Circ Res. 2017;120 (10 ):1674–1686. doi: 10.1161/CIRCRESAHA.117.309419.28495997
54 György B, Szabó TG, Pásztói M, et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci. 2011;68 (16 ):2667–2688. doi: 10.1007/s00018-011-0689-3.21560073
55 Jamaly S, Basavaraj MG, Starikova I, et al. Elevated plasma levels of P-selectin glycoprotein ligand-1-positive microvesicles in patients with unprovoked venous thromboembolism. J Thromb Haemost. 2018;16 (8 ):1546–1554. doi: 10.1111/jth.14162.
56 Bergen K, Mobarrez F, Jörneskog G, et al. High levels of endothelial and platelet microvesicles in patients with type 1 diabetes irrespective of microvascular complications. Thromb Res. 2020;196 :78–86. doi: 10.1016/j.thromres.2020.08.012.32853980
57 Ramirez MI, Amorim MG, Gadelha C, et al. Technical challenges of working with extracellular vesicles. Nanoscale. 2018;10 (3 ):881–906. doi: 10.1039/c7nr08360b.29265147
58 Srikanthan K, Feyh A, Visweshwar H, et al. Systematic review of metabolic syndrome biomarkers: a panel for early detection, management, and risk stratification in the West Virginian population. Int J Med Sci. 2016;13 (1 ):25–38. doi: 10.7150/ijms.13800.26816492
59 Thom SR, Bhopale VM, Yang M. Neutrophils generate microparticles during exposure to inert gases due to cytoskeletal oxidative stress. J Biol Chem. 2014;289 (27 ):18831–18845. doi: 10.1074/jbc.M113.543702.24867949
60 Tøndel BG, Morelli VM, Hansen J-B, et al. Risk factors and predictors for venous thromboembolism in people with ischemic stroke: a systematic review. J Thromb Haemost. 2022;20 (10 ):2173–2186. doi: 10.1111/jth.15813.35815351
61 Peng Y-H, Lin Y-S, Chen C-H, et al. Type 1 diabetes is associated with an increased risk of venous thromboembolism: a retrospective population-based cohort study. PLoS One. 2020;15 (1 ):e0226997. doi: 10.1371/journal.pone.0226997.31935226
62 Cohn DM, Hermanides J, DeVries JH, et al. Stress-induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty: analysis from the RECORD trials. Thromb Haemost. 2012;107 (2 ):225–231. doi: 10.1160/TH11-07-0447.22187097
63 Bovill EG, van der Vliet A. Venous valvular stasis-associated hypoxia and thrombosis: what is the link? Annu Rev Physiol. 2011;73 (1 ):527–545. doi: 10.1146/annurev-physiol-012110-142305.21034220
64 Low PS. Structure and function of the cytoplasmic domain of band 3: center of erythrocyte membrane-peripheral protein interactions. Biochim Biophys Acta. 1986;864 (2 ):145–167. doi: 10.1016/0304-4157(86)90009-2.2943319
65 Messana I, Orlando M, Cassiano L, et al. Human erythrocyte metabolism is modulated by the O2-linked transition of hemoglobin. FEBS Lett. 1996;390 (1 ):25–28. doi: 10.1016/0014-5793(96)00624-2.8706822
66 Fukami MH, Holmsen H, Salganicoff L. Adenine nucleotide metabolism of blood platelets. IX. Time course of secretion and changes in energy metabolism in thrombin-treated platelets. Biochim Biophys Acta. 1976;444 (3 ):633–643. doi: 10.1016/0304-4165(76)90310-x.10970
67 Crowell JW, Houston B. Effect of acidity on blood coagulation. Am J Physiol. 1961;201 (2 ):379–382. doi: 10.1152/ajplegacy.1961.201.2.379.13696662
68 Chen P, Zuo H, Xiong H, et al. Gpr132 sensing of lactate mediates tumor-macrophage interplay to promote breast cancer metastasis. Proc Natl Acad Sci U S A. 2017;114 (3 ):580–585. doi: 10.1073/pnas.1614035114.28049847
69 Colegio OR, Chu N-Q, Szabo AL, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513 (7519 ):559–563. doi: 10.1038/nature13490.25043024
70 Barresi V, Napoli S, Spampinato G, et al. Dectin-1 and TIM3 expression in deep vein thrombosis of lower limbs (DVTLL). J Clin Med. 2020;9 (11 ):3466. doi: 10.3390/jcm9113466.33126475
71 Hao S, Meng J, Zhang Y, et al. Macrophage phenotypic mechanomodulation of enhancing bone regeneration by superparamagnetic scaffold upon magnetization. Biomaterials. 2017;140 :16–25. doi: 10.1016/j.biomaterials.2017.06.013.28623721
72 Egawa M, Mukai K, Yoshikawa S, et al. Inflammatory monocytes recruited to allergic skin acquire an anti-inflammatory M2 phenotype via basophil-derived interleukin-4. Immunity. 2013;38 (3 ):570–580. doi: 10.1016/j.immuni.2012.11.014.23434060
73 Salemi R, Gattuso G, Tomasello B, et al. Co-occurrence of interleukin-6 receptor Asp358Ala variant and high plasma levels of IL-6: an evidence of IL-6 trans-signaling activation in deep vein thrombosis (DVT) patients. Biomolecules. 2022;12 (5 ):681. doi: 10.3390/biom12050681.35625609
74 Cambien B, Bergmeier W, Saffaripour S, et al. Antithrombotic activity of TNF-alpha. J Clin Invest. 2003;112 (10 ):1589–1596. doi: 10.1172/JCI19284.14617760
75 Pircher J, Merkle M, Wörnle M, et al. Prothrombotic effects of tumor necrosis factor alpha in vivo are amplified by the absence of TNF-alpha receptor subtype 1 and require TNF-alpha receptor subtype 2. Arthritis Res Ther. 2012;14 (5 ):R225. doi: 10.1186/ar4064.23079185
76 Nosaka M, Ishida Y, Kimura A, et al. Contribution of the TNF-α (tumor necrosis factor-α)-TNF-Rp55 (tumor necrosis factor receptor p55) axis in the resolution of venous thrombus. Arterioscler Thromb Vasc Biol. 2018;38 (11 ):2638–2650. doi: 10.1161/ATVBAHA.118.311194.30354252
77 Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabet Compl. 2001;15 (1 ):44–54. doi: 10.1016/s1056-8727(00)00132-x.
78 Jones RL, Peterson CM. Reduced fibrinogen survival in diabetes mellitus. A reversible phenomenon. J Clin Invest. 1979;63 (3 ):485–493. doi: 10.1172/JCI109326.429567
79 Assert R, Scherk G, Bumbure A, et al. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia. 2001;44 (2 ):188–195. doi: 10.1007/s001250051598.11270675
80 Spectre G, Östenson C-G, Li N, et al. Postprandial platelet activation is related to postprandial plasma insulin rather than glucose in patients with type 2 diabetes. Diabetes. 2012;61 (9 ):2380–2384. doi: 10.2337/db11-1806.22688337
81 Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest. 1996;98 (4 ):894–898. doi: 10.1172/JCI118871.8770859
82 Dimmeler S, Fleming I, Fisslthaler B, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399 (6736 ):601–605. doi: 10.1038/21224.10376603
83 Denninger JW, Marletta MA. Guanylate cyclase and the.NO/cGMP signaling pathway. Biochim Biophys Acta. 1999;1411 (2–3 ):334–350. doi: 10.1016/s0005-2728(99)00024-9.10320667
84 Sims GP, Rowe DC, Rietdijk ST, et al. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010;28 (1 ):367–388. doi: 10.1146/annurev.immunol.021908.132603.20192808
85 Padilla J, Carpenter AJ, Das NA, et al. TRAF3IP2 mediates high glucose-induced endothelin-1 production as well as endothelin-1-induced inflammation in endothelial cells. Am J Physiol Heart Circ Physiol. 2018;314 (1 ):H52–H64. doi: 10.1152/ajpheart.00478.2017.28971844
86 Zhang Y, Liu J, Jia W, et al. AGEs/RAGE blockade downregulates Endothenin-1 (ET-1), mitigating human umbilical vein endothelial cells (HUVEC) injury in deep vein thrombosis (DVT). Bioengineered. 2021;12 (1 ):1360–1368. doi: 10.1080/21655979.2021.1917980.33896376
87 Doggen CJM, Smith NL, Lemaitre RN, et al. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol. 2004;24 (10 ):1970–1975. doi: 10.1161/01.ATV.0000143134.87051.46.15331431
88 Deguchi H, Pecheniuk NM, Elias DJ, et al. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation. 2005;112 (6 ):893–899. doi: 10.1161/CIRCULATIONAHA.104.521344.16087810
89 Holst AG, Jensen G, Prescott E. Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation. 2010;121 (17 ):1896–1903. doi: 10.1161/CIRCULATIONAHA.109.921460.20404252
90 Obermayer G, Afonyushkin T, Binder CJ. Oxidized low-density lipoprotein in inflammation-driven thrombosis. J Thromb Haemost. 2018;16 (3 ):418–428. doi: 10.1111/jth.13925.29316215
91 Seplowitz AH, Chien S, Smith FR. Effects of lipoproteins on plasma viscosity. Atherosclerosis. 1981;38 (1-2 ):89–95. doi: 10.1016/0021-9150(81)90107-6.7470209
92 Juhan-Vague I, Pyke SD, Alessi MC, et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation. 1996;94 (9 ):2057–2063. doi: 10.1161/01.cir.94.9.2057.8901651
93 Binder CJ, Papac-Milicevic N, Witztum JL. Innate sensing of oxidation-specific epitopes in health and disease. Nat Rev Immunol. 2016;16 (8 ):485–497. doi: 10.1038/nri.2016.63.27346802
94 Miller YI, Shyy JYJ. Context-dependent role of oxidized lipids and lipoproteins in inflammation. Trends Endocrinol Metab. 2017;28 (2 ):143–152. doi: 10.1016/j.tem.2016.11.002.27931771
95 Ardlie NG, Selley ML, Simons LA. Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis. 1989;76 (2-3 ):117–124. doi: 10.1016/0021-9150(89)90094-4.2730708
96 Podrez EA, Byzova TV, Febbraio M, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med. 2007;13 (9 ):1086–1095. doi: 10.1038/nm1626.17721545
97 Badrnya S, Schrottmaier WC, Kral JB, et al. Platelets mediate oxidized low-density lipoprotein-induced monocyte extravasation and foam cell formation. Arterioscler Thromb Vasc Biol. 2014;34 (3 ):571–580. doi: 10.1161/ATVBAHA.113.302919.24371083
98 Huber J, Vales A, Mitulovic G, et al. Oxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-endothelial interactions. Arterioscler Thromb Vasc Biol. 2002;22 (1 ):101–107. doi: 10.1161/hq0102.101525.11788468
99 Shih PT, Elices MJ, Fang ZT, et al. Minimally modified low-density lipoprotein induces monocyte adhesion to endothelial connecting segment-1 by activating beta1 integrin. J Clin Invest. 1999;103 (5 ):613–625. doi: 10.1172/JCI5710.10074478
100 Vora DK, Fang ZT, Liva SM, et al. Induction of P-selectin by oxidized lipoproteins. Separate effects on synthesis and surface expression. Circ Res. 1997;80 (6 ):810–818. doi: 10.1161/01.res.80.6.810.9168783
101 Bochkov VN, Oskolkova OV, Birukov KG, et al. Generation and biological activities of oxidized phospholipids. Antioxid Redox Signal. 2010;12 (8 ):1009–1059. doi: 10.1089/ars.2009.2597.19686040
102 Lehr HA, Krombach F, Münzing S, et al. In vitro effects of oxidized low density lipoprotein on CD11b/CD18 and L-selectin presentation on neutrophils and monocytes with relevance for the in vivo situation. Am J Pathol. 1995;146 (1 ):218–227.7531948
103 Awasthi D, Nagarkoti S, Kumar A, et al. Oxidized LDL induced extracellular trap formation in human neutrophils via TLR-PKC-IRAK-MAPK and NADPH-oxidase activation. Free Radic Biol Med. 2016;93 :190–203. doi: 10.1016/j.freeradbiomed.2016.01.004.26774674
104 Aviram M, Presser D. Oxidized low-density lipoprotein reduces plasma coagulation in vitro. Scand J Clin Lab Invest. 1991;51 (1 ):17–21. doi: 10.1080/00365513.1991.11978684.2020827
105 Kumagai T, Hoshi Y, Tsutsumi H, et al. Inhibition of plasma coagulation through interaction between oxidized low-density lipoprotein and blood coagulation factor VIII. Biol Pharm Bull. 2005;28 (6 ):952–956. doi: 10.1248/bpb.28.952.15930725
106 Rota S, McWilliam NA, Baglin TP, et al. Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E. Blood. 1998;91 (2 ):508–515. doi: 10.1182/blood.V91.2.508.9427704
107 Weinstein EA, Li H, Lawson JA, et al. Prothrombinase acceleration by oxidatively damaged phospholipids. J Biol Chem. 2000;275 (30 ):22925–22930. doi: 10.1074/jbc.M002438200.10801844
108 Luo P, Yuan Q, Wan X, et al. A two-sample Mendelian randomization study of circulating lipids and deep venous thrombosis. Sci Rep. 2023;13 (1 ):7432. doi: 10.1038/s41598-023-34726-3.37156934
109 Kumar NG, Contaifer D, Madurantakam P, et al. Dietary bioactive fatty acids as modulators of immune function: implications on human health. Nutrients. 2019;11 (12 ):11. doi: 10.3390/nu11122974.
110 Hottz ED, Lopes JF, Freitas C, et al. Platelets mediate increased endothelium permeability in dengue through NLRP3-inflammasome activation. Blood. 2013;122 (20 ):3405–3414. doi: 10.1182/blood-2013-05-504449.24009231
111 Semple JW, Italiano JE, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011;11 (4 ):264–274. doi: 10.1038/nri2956.21436837
112 A unified nomenclature system for the nuclear receptor superfamily. Cell. 1999;97 :161–163.10219237
113 Grygiel-Górniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications – a review. Nutr J. 2014;13 (1 ):17. doi: 10.1186/1475-2891-13-17.24524207
114 Michalik L, Auwerx J, Berger JP, et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev. 2006;58 (4 ):726–741. doi: 10.1124/pr.58.4.5.17132851
115 Patsouris D, Reddy JK, Müller M, et al. Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. Endocrinology. 2006;147 (3 ):1508–1516. doi: 10.1210/en.2005-1132.16357043
116 Garcia-Roves P, Huss JM, Han D-H, et al. Raising plasma fatty acid concentration induces increased biogenesis of mitochondria in skeletal muscle. Proc Natl Acad Sci U S A. 2007;104 (25 ):10709–10713. doi: 10.1073/pnas.0704024104.17548828
117 Li L, Zhou J, Wang S, et al. Critical role of peroxisome proliferator-activated receptor α in promoting platelet hyperreactivity and thrombosis under hyperlipidemia. Haematologica. 2022;107 (6 ):1358–1373. doi: 10.3324/haematol.2021.279770.34615341
118 Carson SD. Plasma high density lipoproteins inhibit the activation of coagulation factor X by factor VIIa and tissue factor. FEBS Lett. 1981;132 (1 ):37–40. doi: 10.1016/0014-5793(81)80422-x.6795061
119 Griffin JH, Kojima K, Banka CL, et al. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest. 1999;103 (2 ):219–227. doi: 10.1172/JCI5006.9916134
120 Sureda A, Martorell M, Bibiloni MDM, et al. Effect of free fatty acids on inflammatory gene expression and hydrogen peroxide production by ex vivo blood mononuclear cells. Nutrients. 2020;12 (1 ):146. doi: 10.3390/nu12010146.31947975
121 Boulos P, Kouroukis C, Blake G. Superior sagittal sinus thrombosis occurring at high altitude associated with protein C deficiency. Acta Haematol. 1999;102 (2 ):104–106. doi: 10.1159/000040980.10529516
122 Jha SK, Anand AC, Sharma V, et al. Stroke at high altitude: Indian experience. High Alt Med Biol. 2002;3 (1 ):21–27. doi: 10.1089/152702902753639513.12006161
123 Anand AC, Saha A, Seth AK, et al. Symptomatic portal system thrombosis in soldiers due to extended stay at extreme altitude. J Gastroenterol Hepatol. 2005;20 (5 ):777–783. doi: 10.1111/j.1440-1746.2005.03723.x.15853994
124 Emmi G, Silvestri E, Squatrito D, et al. Thrombosis in vasculitis: from pathogenesis to treatment. Thromb J. 2015;13 (1 ):15. doi: 10.1186/s12959-015-0047-z.25883536
125 Becatti M, Mannucci A, Argento FR, et al. Super-resolution microscopy reveals an altered fibrin network in cirrhosis: the key role of oxidative stress in fibrinogen structural modifications. Antioxidants (Basel). 2020;9 (8 ):9. doi: 10.3390/antiox9080737.
126 Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27 (1 ):229–265. doi: 10.1146/annurev.immunol.021908.132715.19302040
127 Gupta N, Sahu A, Prabhakar A, et al. Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia. Proc Natl Acad Sci U S A. 2017;114 (18 ):4763–4768. doi: 10.1073/pnas.1620458114.28420787
128 Signorelli SS, Scuto S, Marino E, et al. Oxidative stress in peripheral arterial disease (PAD) mechanism and biomarkers. Antioxidants (Basel). 2019;8 (9 ):367. doi: 10.3390/antiox8090367.
129 Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol. 2001;154 (3 ):485–490. doi: 10.1083/jcb.200105058.11489912
130 Denis MM, Tolley ND, Bunting M, et al. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell. 2005;122 (3 ):379–391. doi: 10.1016/j.cell.2005.06.015.16096058
131 Candido S, Lumera G, Barcellona G, et al. Direct oral anticoagulant treatment of deep vein thrombosis reduces IL-6 expression in peripheral mono-nuclear blood cells. Exp Ther Med. 2020;20 (6 ):237–231. doi: 10.3892/etm.2020.9367.33193842
132 Malaponte G, Signorelli SS, Bevelacqua V, et al. Increased levels of NF-kB-dependent markers in cancer-associated deep venous thrombosis. PLoS One. 2015;10 (7 ):e0132496. doi: 10.1371/journal.pone.0132496.26192925
133 Najem MY, Couturaud F, Lemarié CA. Cytokine and chemokine regulation of venous thromboembolism. J Thromb Haemost. 2020;18 (5 ):1009–1019. doi: 10.1111/jth.14759.32020753
134 Wu C, Lu W, Zhang Y, et al. Inflammasome activation triggers blood clotting and host death through pyroptosis. Immunity. 2019;50 (6 ):1401–1411.e4. doi: 10.1016/j.immuni.2019.04.003.31076358
135 Rink TJ, Sage SO. Calcium signaling in human platelets. Annu Rev Physiol. 1990;52 (1 ):431–449. doi: 10.1146/annurev.ph.52.030190.002243.2158766
136 Tyagi T, Ahmad S, Gupta N, et al. Altered expression of platelet proteins and calpain activity mediate hypoxia-induced prothrombotic phenotype. Blood. 2014;123 (8 ):1250–1260. doi: 10.1182/blood-2013-05-501924.24297866
137 Raskob GE, Angchaisuksiri P, Blanco AN, et al. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014;34 (11 ):2363–2371. doi: 10.1161/ATVBAHA.114.304488.25304324
138 Kovacic JC, Moreno P, Hachinski V, et al. Cellular senescence, vascular disease, and aging: part 1 of a 2 – part review. Circulation. 2011;123 (15 ):1650–1660. doi: 10.1161/CIRCULATIONAHA.110.007021.21502583
139 Versteeg HH, Heemskerk JWM, Levi M, et al. New fundamentals in hemostasis. Physiol Rev. 2013;93 (1 ):327–358. doi: 10.1152/physrev.00016.2011.23303912
140 Bettiol A, Becatti M, Silvestri E, et al. Neutrophil-mediated mechanisms of damage and in-vitro protective effect of colchicine in non-vascular Behçet’s syndrome. Clin Exp Immunol. 2021;206 (3 ):410–421. doi: 10.1111/cei.13664.34562315
141 Wang Q, Zennadi R. Oxidative stress and thrombosis during aging: the roles of oxidative stress in RBCs in venous thrombosis. Int J Mol Sci. 2020;21 (12 ):4259. doi: 10.3390/ijms21124259.
142 Barodka VM, Nagababu E, Mohanty JG, et al. New insights provided by a comparison of impaired deformability with erythrocyte oxidative stress for sickle cell disease. Blood Cells Mol Dis. 2014;52 (4 ):230–235. doi: 10.1016/j.bcmd.2013.10.004.24246527
143 Whelihan MF, Zachary V, Orfeo T, et al. Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation. Blood. 2012;120 (18 ):3837–3845. doi: 10.1182/blood-2012-05-427856.22968460
144 Belcher JD, Chen C, Nguyen J, et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood. 2014;123 (3 ):377–390. doi: 10.1182/blood-2013-04-495887.24277079
145 Chen G, Zhang D, Fuchs TA, et al. Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. Blood. 2014;123 (24 ):3818–3827. doi: 10.1182/blood-2013-10-529982.24620350
146 Colas R, Sassolas A, Guichardant M, et al. LDL from obese patients with the metabolic syndrome show increased lipid peroxidation and activate platelets. Diabetologia. 2011;54 (11 ):2931–2940. doi: 10.1007/s00125-011-2272-8.21847583
147 Signorelli SS, Conti GO, Fiore M, et al. Inter-relationship between platelet-derived microparticles and oxidative stress in patients with venous thromboembolism. Antioxidants (Basel). 2020;9 (12 ):9. doi: 10.3390/antiox9121217.
148 Signorelli SS, Oliveri Conti G, Fiore M, et al. Platelet-derived microparticles (MPs) and thrombin generation velocity in deep vein thrombosis (DVT): results of a case-control study. Vasc Health Risk Manag. 2020;16 :489–495. doi: 10.2147/VHRM.S236286.33273818
149 Rattan V, Sultana C, Shen Y, et al. Oxidant stress-induced transendothelial migration of monocytes is linked to phosphorylation of PECAM-1. Am J Physiol. 1997;273 (3 Pt 1 ):E453–E461. doi: 10.1152/ajpendo.1997.273.3.E453.9316433
150 Chelombitko MA, Fedorov AV, Ilyinskaya OP, et al. Role of reactive oxygen species in mast cell degranulation. Biochemistry (Mosc). 2016;81 (12 ):1564–1577. doi: 10.1134/S000629791612018X.28259134
151 den Heijer M. Hyperhomocysteinaemia as a risk factor for venous thrombosis: an update of the current evidence. Clin Chem Lab Med. 2003;41 (11 ):1404–1407. doi: 10.1515/CCLM.2003.215.14656017
152 McCully KS. Homocysteine metabolism, atherosclerosis, and diseases of aging. Compr Physiol. 2015;6 (1 ):471–505. doi: 10.1002/cphy.c150021.26756640
153 Liao JK. Linking endothelial dysfunction with endothelial cell activation. J Clin Invest. 2013;123 (2 ):540–541. doi: 10.1172/JCI66843.23485580
154 Silverman MD, Tumuluri RJ, Davis M, et al. Homocysteine upregulates vascular cell adhesion molecule-1 expression in cultured human aortic endothelial cells and enhances monocyte adhesion. Arterioscler Thromb Vasc Biol. 2002;22 (4 ):587–592. doi: 10.1161/01.atv.0000014221.30108.08.11950695
155 Cueto R, Zhang L, Shan HM, et al. Identification of homocysteine-suppressive mitochondrial ETC complex genes and tissue expression profile – novel hypothesis establishment. Redox Biol. 2018;17 :70–88. doi: 10.1016/j.redox.2018.03.015.29679893
156 Huo Y, Li J, Qin X, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA. 2015;313 (13 ):1325–1335. doi: 10.1001/jama.2015.2274.25771069
157 Ostrakhovitch EA, Tabibzadeh S. Homocysteine and age-associated disorders. Ageing Res Rev. 2019;49 :144–164. doi: 10.1016/j.arr.2018.10.010.30391754
158 Sanderson SM, Gao X, Dai Z, et al. Methionine metabolism in health and cancer: a nexus of diet and precision medicine. Nat Rev Cancer. 2019;19 (11 ):625–637. doi: 10.1038/s41568-019-0187-8.31515518
159 Flora GD, Nayak MK, Ghatge M, et al. Metabolic targeting of platelets to combat thrombosis: dawn of a new paradigm? Cardiovasc Res. 2023;119 (15 ):2497–2507. doi: 10.1093/cvr/cvad149.37706546
160 Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92 (2 ):199–205. doi: 10.3324/haematol.10516.17296569
161 Manke M-C, Ahrends R, Borst O. Platelet lipid metabolism in vascular thrombo-inflammation. Pharmacol Ther. 2022;237 :108258. doi: 10.1016/j.pharmthera.2022.108258.35908612
162 Stojkov D, Gigon L, Peng S, et al. Physiological and pathophysiological roles of metabolic pathways for NET formation and other neutrophil functions. Front Immunol. 2022;13 :826515. doi: 10.3389/fimmu.2022.826515.35251008
163 Brill A, Fuchs TA, Savchenko AS, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. 2012;10 (1 ):136–144. doi: 10.1111/j.1538-7836.2011.04544.x.22044575
164 Stark K, Philippi V, Stockhausen S, et al. Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice. Blood. 2016;128 (20 ):2435–2449. doi: 10.1182/blood-2016-04-710632.27574188
165 Aukrust SG, Holte KB, Opstad TB, et al. NETosis in long-term type 1 diabetes mellitus and its link to coronary artery disease. Front Immunol. 2021;12 :799539. doi: 10.3389/fimmu.2021.799539.35069582
166 Mühl D, Füredi R, Cristofari J, et al. Evaluation of oxidative stress in the thrombolysis of pulmonary embolism. J Thromb Thrombolysis. 2006;22 (3 ):221–228. doi: 10.1007/s11239-006-9035-2.17111195
167 Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol. 2004;24 (6 ):1023–1030. doi: 10.1161/01.ATV.0000128897.54893.26.15105281
168 Halici B, Sarinc Ulasli S, Günay E, et al. Assessment of inflammatory biomarkers and oxidative stress in pulmonary thromboembolism: follow-up results. Inflammation. 2014;37 (4 ):1186–1190. doi: 10.1007/s10753-014-9844-y.24531854
169 Ndrepepa G. Myeloperoxidase – a bridge linking inflammation and oxidative stress with cardiovascular disease. Clin Chim Acta. 2019;493 :36–51. doi: 10.1016/j.cca.2019.02.022.30797769
170 Kapoor S, Opneja A, Nayak L. The role of neutrophils in thrombosis. Thromb Res. 2018;170 :87–96. doi: 10.1016/j.thromres.2018.08.005.30138777
171 Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303 (5663 ):1532–1535. doi: 10.1126/science.1092385.15001782
172 Lewis HD, Liddle J, Coote JE, et al. Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat Chem Biol. 2015;11 (3 ):189–191. doi: 10.1038/nchembio.1735.25622091
173 Ward CM, Tetaz TJ, Andrews RK, et al. Binding of the von Willebrand factor A1 domain to histone. Thromb Res. 1997;86 (6 ):469–477. doi: 10.1016/s0049-3848(97)00096-0.9219327
174 von Brühl M-L, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012;209 (4 ):819–835. doi: 10.1084/jem.20112322.22451716
175 Massberg S, Grahl L, von Bruehl M-L, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med. 2010;16 (8 ):887–896. doi: 10.1038/nm.2184.20676107
176 Maratou E, Dimitriadis G, Kollias A, et al. Glucose transporter expression on the plasma membrane of resting and activated white blood cells. Eur J Clin Invest. 2007;37 (4 ):282–290. doi: 10.1111/j.1365-2362.2007.01786.x.17373964
177 Amini P, Stojkov D, Felser A, et al. Neutrophil extracellular trap formation requires OPA1-dependent glycolytic ATP production. Nat Commun. 2018;9 (1 ):2958. doi: 10.1038/s41467-018-05387-y.30054480
178 Fossati G, Moulding DA, Spiller DG, et al. The mitochondrial network of human neutrophils: role in chemotaxis, phagocytosis, respiratory burst activation, and commitment to apoptosis. J Immunol. 2003;170 (4 ):1964–1972. doi: 10.4049/jimmunol.170.4.1964.12574365
179 Alba-Loureiro TC, Munhoz CD, Martins JO, et al. Neutrophil function and metabolism in individuals with diabetes mellitus. Braz J Med Biol Res. 2007;40 (8 ):1037–1044. doi: 10.1590/s0100-879x2006005000143.17665039
180 Six E, Lagresle-Peyrou C, Susini S, et al. AK2 deficiency compromises the mitochondrial energy metabolism required for differentiation of human neutrophil and lymphoid lineages. Cell Death Dis. 2015;6 (8 ):e1856–e1856. doi: 10.1038/cddis.2015.211.26270350
181 Li H, Tan H, Liu Z, et al. Succinic acid exacerbates experimental autoimmune uveitis by stimulating neutrophil extracellular traps formation via SUCNR1 receptor. Br J Ophthalmol. 2022;107 (11 ):1744–1749. doi: 10.1136/bjophthalmol-2021-320880.35346946
182 Manosalva C, Quiroga J, Hidalgo AI, et al. Role of lactate in inflammatory processes: friend or foe. Front Immunol. 2021;12 :808799. doi: 10.3389/fimmu.2021.808799.35095895
183 Conejeros I, López-Osorio S, Zhou E, et al. Glycolysis, monocarboxylate transport, and purinergic signaling are key events in Eimeria bovis-induced NETosis. Front Immunol. 2022;13 :842482. doi: 10.3389/fimmu.2022.842482.36032127
184 Burgos RA, Werling D, Hermosilla CR. Editorial: the emerging role of metabolism and metabolic-related receptors on neutrophil extracellular traps (NET) formation. Front Immunol. 2022;13 :1028228. doi: 10.3389/fimmu.2022.1028228.36238307
185 Hakkim A, Fuchs TA, Martinez NE, et al. Activation of the Raf-MEK-ERK pathway is required for neutrophil extracellular trap formation. Nat Chem Biol. 2011;7 (2 ):75–77. doi: 10.1038/nchembio.496.21170021
